MetaVia to Showcase Obesity and MASH Data at ADA 2026
Event summary
- MetaVia to present three late-breaking posters at ADA 2026 on June 7, 2026.
- DA-1726 Phase 1 higher-dose cohort results to be unveiled.
- Vanoglipel combination therapy data for MASH and Type 2 diabetes presented.
- DA-1726 Phase 1 Part 3 titration study results expected Q4 2026.
The big picture
MetaVia's presentation at ADA 2026 highlights its focus on developing next-generation therapies for obesity and metabolic diseases. The company's dual approach with DA-1726 and vanoglipel positions it in a competitive landscape dominated by established GLP-1 agonists and emerging combination therapies. The upcoming data could validate MetaVia's differentiation strategy and attract partnering interest.
What we're watching
- Clinical Efficacy
- Whether DA-1726's Phase 1 higher-dose cohort demonstrates superior weight loss and tolerability compared to competitors.
- Combination Therapy Potential
- The therapeutic potential of vanoglipel in combination with existing treatments for MASH and Type 2 diabetes.
- Regulatory Pathway
- The pace at which MetaVia can advance DA-1726 and vanoglipel through clinical trials and potential regulatory approval.
Related topics